Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia
Cue-based Intervention in Prospective Memory and Medication Adherence.
Medication adherence is a major challenge while treating patients with major mental illnesses like schizophrenia and schizoaffective disorder.
- Trial name
- NCT06474195
- Testing
- Cue based intervention, Treatment as Usual
- Where
- India
- Volunteers
- 104 people
- Sponsor
- University of Pittsburgh
Bipolar Disorder, Major Depressive Disorder
A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women
Pregnant women who are taking lamotrigine will be evaluated monthly during pregnancy including a clinical evaluation and a blood draw for lamotrigine levels at each visit.
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
- Trial name
- NCT03774641
- Testing
- Lamictal
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Schizophrenia, Schizoaffective Disorder
Seroquel Long-Term NIS for Schizophrenia Patients
To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder
- Trial name
- SELECT (NCT00523783)
- Where
- 3 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Schizoaffective Disorder, Bipolar Type, Bipolar Disorder
Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues
Psychoneuromentalism Disorder is a disorder arising in the mind; that is related to the mental and emotional state of a person. It is the science of mental life. The body has a natural design to heal itself.
- Conditions
- Schizoaffective Disorder, Bipolar Type, Bipolar Disorder, ADHD - Combined Type, Dissociative Disorder
- Trial name
- PNMD (NCT06235177)
- Testing
- Decompartmentalization Framework, Liquid Herbal TInctures, Mental Imagery
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Essence of Integrative Health and Medicine Practice
Schizophrenia
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.
- Trial name
- NCT00892021
- Testing
- NSA-789
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Schizoaffective Disorders
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Psychotic Disorders
- Trial name
- RAPID (NCT00457899)
- Testing
- Quetiapine IR (Immediate Release)
- Where
- 12 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Bioavailability of LY03004 and Risperdal® Consta®
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
- Trial name
- NCT02091388
- Testing
- LY03004, Risperdal® Consta®
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Study of Vitamin D in the Severely Mentally Ill
Supplementation of Vitamin D in those with low levels will increase the level and result in some improvement in health and psychopathology measures.
- Trial name
- NCT01169142
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophrenia, Schizoaffective Disorder
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
This study will examine brain metabolic and excitatory/inhibitory mechanisms related to cognitive and visual functioning in adults with schizophrenia and healthy control participants.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
- Trial name
- NCT07788755
- Testing
- Perceptual Discrimination Training, Cognitive Control Training
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Schizoaffective Disorder
Systematic Evaluation of Antiviral Medication in Schizophrenia
The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes…
- Trial name
- SEAMS (NCT00514449)
- Testing
- Valacyclovir
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Konasale Prasad
Schizophrenia and Schizoaffective Disorder
Relationship Between Physical Fitness and Psychopathology, Cognition and Quality of Life in Patients Diagnosed With Schizophrenia: a Mixed Method Study.
The goal of this observational study is to assess the physical fitness and the influence of possible factors (disease symptomatology, cognitive status, patient functioning and degree of perceived quality of life) on patients…
- Trial name
- COFESQ (NCT06824584)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Universidade da Coruña
Schizophrenia, Psychotic Disorders
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone…
- Trial name
- NCT00236548
- Testing
- risperidone
- Volunteers
- 1 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Artemisinin to Reduce The Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
- Trial name
- NCT00753506
- Testing
- Artemisinin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Schizo Affective Disorder
Cognitive Effects of Nimodipine in Patients With Schizophrenia
This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional…
- Trial name
- NCT03671525
- Testing
- Nimodipine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.